Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2025-04-09 00:00:00 ET · period of report 2025-04-07 · accession 0001415889-25-010482 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-09 | 2025-04-07 | KNSA | Patel Sanj K | COB, CEO, Dir | M - OptEx | — | +9,992 | 101.5K | +11% | — |
| D | 2025-04-09 | 2025-04-07 | KNSA | Patel Sanj K | COB, CEO, Dir | F - Tax | $20.28 | -4,832 | 96.7K | -5% | -$98.0K |
| D | 2025-04-09 | 2025-04-07 | KNSA | Patel Sanj K | COB, CEO, Dir | M - OptEx | $0.00 | -9,992 | 9,991 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2025-04-07 | M | A | 9,992 | — | 101,506 | D | — | — | (F1) Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| 2 | Common | Class A Ordinary Share | 2025-04-07 | F | D | 4,832 | $20.28 | 96,674 | D | — | — | |
| 3 | Derivative | Restricted Share Unit | 2025-04-07 | M | D | 9,992 | $0.00 | 9,991 | D | — · — to — | 9,992 Class A Ordinary Share | (F1) Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. (F2) The RSUs vest over a four-year period, with 25% of the RSs vesting on the yearly anniversary of the grant date, April 7, 2022. |